Intralesional therapy for in-transit and satellite metastases in melanoma

Kendra J Feeney; Michael J Mastrangelo

doi:10.1016/j.soc.2014.12.007

Intralesional therapy for in-transit and satellite metastases in melanoma

Surg Oncol Clin N Am. 2015 Apr;24(2):299-308. doi: 10.1016/j.soc.2014.12.007.

Authors

Kendra J Feeney¹, Michael J Mastrangelo²

Affiliations

¹ Department of Medical Oncology, Sidney Kimmel School of Medicine, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA. Electronic address: kendra.feeney@jefferson.edu.
² Department of Medical Oncology, Sidney Kimmel School of Medicine, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA.

PMID: 25769713
DOI: 10.1016/j.soc.2014.12.007

Abstract

Intratumoral therapy with bacteria/bacterial products dates to at least the 1890s. Over the decades this has expanded beyond the use of microbes and microbial products to include chemicals, cancer chemotherapeutic agents, cytokines, recombinant organisms, and hybrid molecules. The appeal of this method of delivery is the ability to deliver high concentrations of the therapeutic agent directly to the tumor, often with minimal side effects. This article summarizes the use and efficacy of the various agents used in the past and present in the treatment of in-transit and satellite metastases in melanoma.

Keywords: Bacille Calmette-Guerin; Granulocyte-macrophage colony-stimulating factor; In-transit disease; Intralesional therapy; Melanoma; Rose bengal; Scarification; Vaccinia.

Publication types

Review

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Antineoplastic Agents / administration & dosage*
Humans
Injections, Intralesional
Melanoma / drug therapy*
Melanoma / pathology
Neoplasm Metastasis / therapy
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Adjuvants, Immunologic
Antineoplastic Agents